Weil’s Antitrust team is representing Actavis in the just announced sale of its Branded Respiratory Portfolio to AstraZeneca, a transaction valued at $600 million. The transaction is subject to antitrust regulatory approval as well as customary closing conditions, and is expected to close in the first quarter of 2015.
Weil’s Antitrust team includes global head of Antitrust/Competition Steven Newborn, partners Ann Malester and Steven Bernstein, counsel Vadim Brusser, and associate Albert Cahn.
Source: www.weil.com
